


# 2<sup>nd</sup> MOVE Symposium



*presented by*

European National Societies for Extracellular vesicles



## Abstract book



# *2<sup>nd</sup> MOVE Symposium*

8-11 October 2024, Belgrade, Serbia

## Organizing Societies




Serbian Society for Extracellular Vesicles, SrbeEVs  
 Austrian Society for Extracellular Vesicles, ASEV  
 Baltic Society for Extracellular Vesicles, BSEV  
 Italian Society for Extracellular Vesicles, EVIta  
 French Society for Extracellular Vesicles, FSEV  
 Spanish Society for Extracellular Vesicles, GEIVEX  
 German Society for Extracellular Vesicles, GSEV  
 United Kingdom Society for Extracellular Vesicles, UKEV

## Supported by Societies



Belgian Society for Extracellular Vesicles, BESEV  
 Czech Society for Extracellular Vesicles, CzeSEV  
 Danish Society for Extracellular Vesicles, DSEV  
 Extracellular Vesicles Network of Ireland, EVI  
 Finnish Society for Extracellular Vesicles, FISEV  
 Hungarian Section for Extracellular Vesicles, HSEV  
 Israeli Society for Extracellular Vesicles, ISREV  
 Netherlands Society for Extracellular Vesicles, NLSEV  
 Norwegian Society for Extracellular Vesicles, Nor-EV  
 Portuguese Network on Extracellular Vesicles, PNEV  
 Polish Society for Extracellular Vesicles, PSEV  
 Slovenian Network for Extracellular Vesicles, SiN-EV  
 Swedish EV Network, Sw-SEV



# *2<sup>nd</sup> MOVE Symposium*

8-11 October 2024, Belgrade, Serbia

## International Organizing Committee

---

Maja Kosanovic, SrBEVs

Beate Riner, ASEV

Alireza Fazeli, BSEVs


Annalisa Radeghieri, EVIta

Christian Neri, FSEV

Pilar Martin-Duque, GEIVEX

Bernd Giebel, GSEV

Charlotte Lawson, UKEV



# *2<sup>nd</sup> MOVE Symposium*

8-11 October 2024, Belgrade, Serbia

## Scientific Committee

---

### **Antonio Marcilla**

Dep. for Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy,  
University of Valencia, Valencia, Spain

### **Alicia Llorente**

Oslo University Hospital, Oslo, Norway

### **Bernd Giebel**

Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany

### **Berta Puig**

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

### **Bojana Milutinović**

Department of Neurosurgery MD Anderson Cancer Center, Houston, USA

### **Dhanu Gupta**

Department of Paediatrics, University of Oxford, United Kingdom

### **Frederik Verweij**

Div. of Cell Biology, Neurobiology & Biophysics, Department of Biology Faculty of Science,  
Utrecht University, Utrecht, The Netherlands

### **Gema Chiva-Blanch**

Health Sciences Studies, Universitat Oberta de Catalunya (UOC) Barcelona, Spain

### **Getnet Midekessa**

Institute of Veterinary Medicine and Animal Sciences, Estonian University of Life Sciences and  
Institute of Biomedicine and Translational Medicine, University of Tartu, Estonia

### **Jason Webber**

Institute of Life Science, Swansea University Medical School, Swansea University, Swansea, UK and  
Tissue Microenvironment Group, School of Medicine, Cardiff University, Cardiff, UK

### **Jessica Gobbo**

Centre Georges-François Leclerc, Dijon, France

### **Lydia Alvarez-Erviti**

Molecular Neurodegeneration Group, Center for Biomedical Research of La Rioja (CIBIR), La Rioja, Spain

### **Michele Guescini**

Biochemistry Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy

### **Michiel Pegtel**

Amsterdam UMC/Cancer Center Amsterdam, Amsterdam, The Netherlands

### **Milica Popović**

Department of Biochemistry, Faculty of Chemistry, University of Belgrade, Belgrade, Serbia

### **Rossella Crescitelli**

Sahlgrenska Center for Cancer Research, University of Gothenburg, Göteborg, Sweden

### **Tanja Jasmin Kutzner**

Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

### **Tobias Tertel**

Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

### **Wolf Holnthoner**

Ludwig-Boltzmann-Institute for Traumatology, Vienna, Austria



## Characterisation of thyroid-originating extracellular vesicles from thyroid cell culture medium and plasma of patients harboring thyroid tumors

Jelena Janković Miljuš<sup>1</sup>, Ninoslav Mitić<sup>1</sup>, Maja Kosanović<sup>1</sup>, Ilona Đorić<sup>1</sup>, Tijana Išić Denčić<sup>1</sup>, Vladan Živaljević<sup>2</sup>, Miloš Žarković<sup>3</sup>, Sonja Šelemetjev<sup>1</sup>

<sup>1</sup>Institute for the Application of Nuclear Energy – INEP, University of Belgrade, Serbia; <sup>2</sup>Clinic for Endocrine Surgery, University Clinical Center of Serbia, Belgrade, Serbia; <sup>3</sup>Faculty of Medicine, University of Belgrade, Belgrade, Serbia

**Introduction:** Postoperative follow-up of differentiated thyroid carcinoma patients based on measuring thyroglobulin (Tg) levels is unreliable in patients with Tg autoantibodies (TgAt). Detecting thyroid markers on extracellular vesicles (EVs) might be a potent way to overcome these issues. We analysed the presence of CD63 (EVs marker) and thyroid-specific markers: thyroid-stimulating hormone receptor (TSHR) and Tg in EVs of thyroid cell lines to optimize detection and later in plasma EVs of thyroid nodule patients.

**Methods:** EVs were isolated by differential ultracentrifugation from thyroid normal (Nthy-ori-3-1) and cancer (TPC-1, OCUT2) cell lines and from patient's plasma (four benign, three malignant, and one recurrent). EVs number and size were measured with NTA. The presence of protein markers was determined using dot-blot.

**Results:** Nthy-ori-3-1 and OCUT2 cells were not viable after 6h of growth in serum-free medium, while TPC-1 cell line was viable until 24h, which influenced the number of isolated EVs. CD63 was present on EVs isolated from all cell lines. TSHR was confirmed in the cell lysate of all cell lines, while only EVs from TPC-1 harbored TSHR on their surface. Tg was present in the cell lysate and EVs originating from Nthy-ori-3-1 and TPC-1 cells, but not OCUT2. Marker analysis showed that plasma EVs from both malignant and benign groups were positive for CD63 and TSHR, and that they contain Tg, while levels of TSHR were higher in the malignant group. Plasma EVs from recurrent patient were positive for all three investigated markers.

**Conclusions:** TSHR found on the surface of thyroid-originating EVs from medium and plasma could allow immunoaffinity-based isolation of thyroid-specific EVs while the presence of Tg in these EVs holds a promise in detecting reliable Tg levels in TgAt recurrent patients. These promising findings need to be validated on a higher number of samples with analysis of Tg localisation.

**Funding information:** The study was supported by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia Grant No. 451-03-66/2024-03/200019.

**Publishers:**

Serbian Society for Extracellular Vesicles, SrbEVs with  
Austrian Society for Extracellular Vesicles, ASEV  
Baltic Society for Extracellular Vesicles, BSEV  
Italian Society for Extracellular Vesicles, EVIta  
French Society for Extracellular Vesicles, FSEV  
Spanish Society for Extracellular Vesicles, GEIVEX  
German Society for Extracellular Vesicles, GSEV  
United Kingdom Society for Extracellular Vesicles, UKEV

**Editors:**

Maja Kosanovic, SrbEVs  
Beate Riner, ASEV  
Alireza Fazeli, BSEVs  
Annalisa Radeghieri, EVIta  
Christian Neri, FSEV  
Pilar Martin-Duque, GEIVEX  
Bernd Giebel, GSEV  
Charlotte Lawson, UKEV

**Technical Editor and Design:**

Maja Kosanović

**ISBN** 978-86-905626-1-9

**Year:** 2024.

**Disclaimer:** The authors are responsible for the contents  
of their abstracts and warrant that their abstract is original.

